[Compound Xuanju capsule for type III and type IV prostatitis: observation of therapeutic results]

To investigate the efficacy and action mechanisms of Compound Xuanju Capsule (CXC) in the treatment of type III and type IV prostatitis.

This study included 88 cases of type III and 18 cases of type IV prostatitis, 14 with male infertility, 27 with ED, and 8 with increased PSA levels. In addition to prostate massage and psychotherapy, the patients were treated with CXC, 3 capsules once, tid, for 3 months. Then changes in relevant indexes were evaluated by the self-control method.

The NIH-CPSI scores of the patients with type III prostatitis were decreased by 47.59% (22.17 +/- 3.48 vs 1.62 +/- 2.53) after 1 month and by 74.61% (22.17 +/- 3.48 vs 5.63 +/- 3.14) after 3 months of CXC medication, with statistically significant differences from the baseline in both the total score and the scores on specific items (P < 0.05). The patients with infertility showed significantly improved sperm quality after treatment as compared with premedication (sperm cone: [12.52 +/- 3.16] x 10(6)/ml vs [28.32 +/- 8.36] x 10(6)/ml, grade a sperm: [10.12 +/- 4.56]% vs [26.06 +/- 10.18]%, grade a + b sperm: [29.89 +/- 8.86]% vs [53.26 +/- 11.29]%) (P < 0.05), and 8 of the patients' spouses got pregnant. Nineteen of the patients with ED were cured, with significant differences in the IIEF-5 score from pretreatment (10.41 +/- 3.65 vs 19.78 +/- 3.00) (P < 0.05). The PSA level was reduced to normal in all the 8 abnormal cases. The WBC count was remarkably decreased and even returned to normal in 19 cases with WBC count > 100/HP ative culture results.

Compound Xuanju Capsule is efficacious for type III and type IV prostatitis and those complicated by infertility, ED, PSA elevation, WBC increase, and negative culture results, with no obvious adverse events.